Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-Positive Early Breast Cancer × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12985 Triple Negative Breast Neoplasms 1132 Neoplasms 740 Ovarian Neoplasms 672 Neoplasm Metastasis 586 Lung Neoplasms 577 Colorectal Neoplasms 571 Prostatic Neoplasms 556 Carcinoma, Non-Small-Cell Lung 528 Pancreatic Neoplasms 377 Melanoma 364 Stomach Neoplasms 347 Colonic Neoplasms 328 Motor Activity 284 Breast Neoplasms, Male 284 Carcinoma, Intraductal, Noninfiltrating 274 Uterine Cervical Neoplasms 262 Head and Neck Neoplasms 261 Endometrial Neoplasms 253 Carcinoma, Renal Cell 213 Sarcoma 201 Urinary Bladder Neoplasms 192 Squamous Cell Carcinoma of Head and Neck 189 Breast Carcinoma In Situ 189 Lymphedema 188 Esophageal Neoplasms 188 Brain Neoplasms 182 Fatigue 164 Carcinoma, Ovarian Epithelial 151 Breast Cancer Female 148

Interventions

pertuzumab 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03674112 2024-01-02

PHranceSCa

Hoffmann-La Roche

Phase 2 Completed

160 enrolled 53 charts

HER2-Positive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡